Payment overview · 2025
General Payments
$430.97
23 reported records · 10 companies
Healthcare provider profile · identity verified
Deann Lois Thompson
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · AVA, MO · NPI 1508039769
Verified facts
What the public records show
CMS Open Payments records show Deann Lois Thompson received $430.97 in general payments during 2025 across 23 reported records.
AstraZeneca Pharmaceuticals LP accounted for 49.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $212.64 | 49.3% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $53.22 | 12.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $29.47 | 6.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $27.57 | 6.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.95 | 5.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.44 | 4.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.17 | 4.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.68 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.47 | 3.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.36 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $430.97 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $107.77 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $91.12 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $71.56 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $53.22 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $53.22 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $29.47 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $27.57 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 114 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 116 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
114 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
116 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
86 | 18 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 311 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 216 | 58 |
| Tizanidine Hcl | Tizanidine Hcl | 206 | 40 |
| Lisinopril | Lisinopril | 205 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 202 | 52 |
| Gabapentin | Gabapentin | 184 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 60 |
| Prednisone | Prednisone | 166 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 37 |
| Omeprazole | Omeprazole | 145 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 33 |
| Losartan Potassium | Losartan Potassium | 120 | 35 |
| Mounjaro | Tirzepatide | 116 | 17 |
| Trazodone Hcl | Trazodone Hcl | 116 | 26 |
| Farxiga | Dapagliflozin Propanediol | 114 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 22 |
| Furosemide | Furosemide | 101 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 42 |
| Clonidine Hcl | Clonidine Hcl | 89 | 15 |
| Baclofen | Baclofen | 86 | 21 |
| Cephalexin | Cephalexin | 86 | 62 |
| Trulicity | Dulaglutide | 86 | 18 |
| Glimepiride | Glimepiride | 85 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 18 |
| Potassium Chloride | Potassium Chloride | 84 | 27 |
| Eliquis | Apixaban | 83 | 18 |
| Fluconazole | Fluconazole | 83 | 44 |
| Doxycycline Hyclate | Doxycycline Hyclate | 81 | 59 |
| Sertraline Hcl | Sertraline Hcl | 78 | 15 |
| Azithromycin | Azithromycin | 76 | 53 |
| Celecoxib | Celecoxib | 73 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 20 |
| Metformin Hcl | Metformin Hcl | 69 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 18 |
| Montelukast Sodium | Montelukast Sodium | 66 | 17 |
| Allopurinol | Allopurinol | 65 | 15 |
| Linzess | Linaclotide | 65 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 14 |
| Simvastatin | Simvastatin | 61 | 18 |
| Meloxicam | Meloxicam | 59 | 18 |
| Carvedilol | Carvedilol | 58 | 14 |
| Ezetimibe | Ezetimibe | 57 | 18 |
| Buspirone Hcl | Buspirone Hcl | 56 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 48 | 13 |
| Mirtazapine | Mirtazapine | 48 | suppressed |
| Ibuprofen | Ibuprofen | 47 | 16 |
| Nitroglycerin | Nitroglycerin | 47 | 25 |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Glipizide | Glipizide | 46 | 11 |
| Meclizine Hcl | Meclizine Hcl | 46 | 11 |
| Ondansetron Odt | Ondansetron | 46 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 14 |
| Ozempic | Semaglutide | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 15 |
| Nystatin | Nystatin | 40 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | suppressed |
| Estradiol | Estradiol | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Mupirocin | Mupirocin | 36 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Naproxen | Naproxen | 31 | 11 |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 17 |
| Famotidine | Famotidine | 28 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 28 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 23 | suppressed |
| Dexamethasone | Dexamethasone | 22 | 20 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Pentoxifylline | Pentoxifylline | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 19 | suppressed |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Constulose | Lactulose | 16 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Lovastatin | Lovastatin | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Misoprostol | Misoprostol | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Repatha Pushtronex | Evolocumab | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $430.97 · 23 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, ENFLONSIA, FARXIGA, GARDASIL 9, INSPIRE, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, VAXNEUVANCE, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error